Vimovo, co-developed by Pozen and AstraZeneca, is a fixed-dose combination of delayed-release enteric-coated naproxen, a pain-relieving NSAID, and immediate-release esomeprazole, a proton pump inhibitor (PPI).

According to AstraZeneca, the FDA approval was supported by data from a clinical development program, including results from the pivotal PN400-301 and PN400-302 studies, which showed patients taking Vimovo experienced fewer endoscopic gastric ulcers, compared to patients receiving enteric-coated naproxen.

In the PN400-301 and 302 studies, the primary end point was the cumulative incidence of gastric ulcers through six months. In each of the trials, patients received either Vimovo or enteric-coated naproxen 500mg, twice daily, over a six-month treatment period. Endoscopies were performed at baseline and at one, three, and six months.

Howard Hutchinson, chief medical officer of AstraZeneca, said: “In a single pill, Vimovo provides a proven pain reliever with a built-in PPI for arthritis patients at-risk for NSAID associated gastric ulcers. The approval also demonstrates the commitment of AstraZeneca and Pozen to provide a new pain relief option that addresses the unmet medical needs of these patients.”

Do you think the approval help the companies to provide a new pain relief option?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.